SEARCH

SEARCH BY CITATION

Please note that there have been changes made to Tables 2 and 3. The changes affect the subcategories listed under Tumor location, TNM stage, and 2010 WHO classification.

The corrected tables are shown below.

The authors regret these errors.

Table 2. Risk Factors Related to Outcomes of Patients With Pancreatic Neuroectodermal Tumors
VariableUnivariate AnalysisMultivariate Analysis
No. of PatientsPaHR (95% CI)Pb
  1. Abbreviations: CI, confidence interval; HR, hazard ratio; MPD, main pancreatic duct; NEC, neuroendocrine carcinoma; NET, neuroendocrine tumor; SSTR-2a, somatostatin receptor type 2A; WHO, World Health Organization.

  2. a

    P values were determined using the Kaplan-Meier method and the log- rank test.

  3. b

    P values were determined using stepwise multivariate analysis with a Cox proportional hazards regression model.

  4. c

    Seventy-nine patients had 83 pancreatic tumors. Patients who had >2 tumors were studied to select the larger ones.

  5. d

    One patient was excluded because of lack of examinations.

  6. e

    Twenty-one patients were excluded because of lack of examinations. Because vascular invasion was assessed only in patients who underwent open surgery, this factor was not included in the multivariate analysis.

  7. f

    Twelve patients were excluded because of lack of examinations.

  8. g

    One patient was excluded because of lack of examinations.

  9. h

    Thirteen patients were excluded because of lack of examinations.

Age at diagnosis, y .3669  
<6044   
>6035   
Sex .2124  
Male37   
Female42   
Tumor function .6871  
Functional15   
Nonfunctional64   
Tumor locationc .5795  
Head25   
Body/Tail54   
Greatest tumor .0007  
dimension, mm    
>2046   
<2033   
Calcification .8895  
Yes13   
No66   
Cyst in the tumord .0774  
Yes16   
No62   
TNM stage .0000  
I/II/III62   
IV17   
Metastasis .0000  
Yes31   
No48   
Vascular invasione .0231  
Yes27   
No31   
MPD invasionf .0681  
Yes14   
No54   
2010 WHO classificationg .000028.889 (7.502-111.240).000
Grade 1 NET/Grade 2 NET64   
NEC12   
SSTR-2a scoreh .00003.611 (1.344-9.702).001
018   
1-348   
Table 3. Comparison of Somatostatin Receptor Type 2A (SSTR-2a)-Negative and SSTR-2a-Positive Pancreatic Neuroectodermal Tumors
VariablePattern of SSTR-2a Score: No. of PatientsPa
SSTR-2a Score 0, n =17SSTR-2a Score 1-3, n = 49
  1. Abbreviations: MPD, main pancreatic duct; NEC, neuroendocrine carcinoma; NET, neuroendocrine tumor; WHO, World Health Organization.

  2. a

    P values were determined with the Fisher exact probability test or the Mann-Whitney U test.

  3. b

    One patient was excluded because of lack of examinations.

  4. c

    One patient was excluded because of lack of examinations.

  5. d

    Sixteen patients were excluded because of lack of examinations.

  6. e

    Eight patients were excluded because of lack of examinations.

  7. f

    Two patients were excluded because of lack of examinations.

Age: Median [range], y60 [19-81]58 [16-86].6973
Sex  .1016
Male1121 
Female628 
Tumor function  .5048
Functional37 
Nonfunctional1442 
Location of tumora  .5917
Head515 
Body/Tail1234 
Greatest tumor dimension: Median [range], mm40 [4-220]20 [2-110].0958
Calcificationb  .6125
Yes27 
No1412 
Cyst in tumorc  .4009
Yes49 
No1240 
TNM stage  .0987
I/II/III1141 
IV68 
Vascular invasiond  .2747
Yes321 
No620 
MPD invasione  .5884
Yes38 
No1235 
2010 WHO classificationf  .0023
Grade 1 NET/Grade 2 NET1044 
NEC73